Key takeaways
- Eli Lilly's oral weight-loss drug Foundayo hit a record high of 38,928 weekly prescriptions in August 2026.
- Novo Nordisk's oral Wegovy pill has hit a market ceiling, making up just 33% of all Wegovy scripts.
- Eli Lilly now controls 60.1% of the total U.S. obesity market share compared to Novo's 39.9%.
- The lack of strict fasting and water requirements for Foundayo is driving patients to favor Lilly's daily pill over oral Wegovy.
What happened
Newly released prescription data reveals that Eli Lilly’s oral weight-loss drug, Foundayo, is gaining significant momentum in the U.S. market, with weekly prescriptions climbing to a record 38,928. At the same time, Novo Nordisk’s rival oral medication, the Wegovy pill, appears to have hit a market share ceiling, falling back to 33% of all Wegovy prescriptions. According to IQVIA data cited by Citi analysts, weekly scripts for the oral version of Wegovy dipped to approximately 163,000, down from a prior peak of roughly 172,000.
Why it matters
For millions of Americans seeking medical weight loss, the daily pill is the most highly anticipated alternative to weekly injections. However, the battle between these needle-free options directly impacts how telehealth providers package and price their brand-name offerings.
While Novo Nordisk enjoyed a powerful first-mover advantage by leveraging its household "Wegovy" brand name, Eli Lilly is rapidly closing the gap with Foundayo. Because Foundayo does not require the strict, highly inconvenient fasting and water restrictions associated with oral semaglutide (the Wegovy pill), patients are increasingly asking their doctors and online providers for Lilly's option. If Foundayo's momentum continues, telehealth platforms may shift their clinical protocols to favor Lilly's pill over Novo's, reshuffling the competitive landscape for cash-paying consumer options.
What the data says
The latest figures from IQVIA for the week ending August 14, 2026, outline a clear divergence in the oral GLP-1 market:
- Foundayo's Rise: Eli Lilly's daily pill recorded 38,928 total weekly scripts, marking its fourth consecutive week of growth (up from 34,219 the prior week and 29,388 two weeks before).
- Wegovy Pill Flatlines: Novo's oral semaglutide dropped to 163,000 weekly scripts. The pill now accounts for 33% of the total Wegovy franchise, down from its recent high of 35%.
- The Overall Obesity Market Split: Total Wegovy weekly prescriptions (injectable and oral combined) fell 1.1% to roughly 495,500. This allowed Eli Lilly’s injectable Zepbound to widen its lead. The overall U.S. obesity market share now stands at 60.1% for Lilly and 39.9% for Novo Nordisk.
- Financial Footprint: In the second quarter of 2026, Lilly reported $98 million in total Foundayo sales, with $67 million originating from the U.S. market.
It is worth noting that analysts at Citi caution that IQVIA's figures may undercount the total volume. There is a potential gap in how IQVIA captures online prescription data, meaning Foundayo's actual growth rate could be even faster through direct-to-consumer telehealth channels.
How it compares
For U.S. buyers comparing their weight-loss options, the choice between the Wegovy pill and Foundayo comes down to daily routine and administration rules.
To achieve maximum absorption, the Wegovy pill (oral semaglutide) must be taken first thing in the morning on an empty stomach with no more than four ounces of plain water, followed by a strict 30-minute fasting period before consuming any food, other beverages, or other medications. Foundayo, a small-molecule oral GLP-1 receptor agonist, frees patients from these strict fasting and water constraints, making it a much easier daily habit to maintain.
In terms of cost, both brand-name oral medications carry high retail list prices that hover around $1,000 per month for cash-paying patients. This is why many patients turn to online platforms to compare providers and seek more affordable alternatives, such as compounding. When comparing compounded vs brand-name semaglutide, compounded liquid options are often substantially cheaper than brand pills, though they require self-injection. For those insistent on brand-name oral medications, navigating commercial insurance coverage or finding telehealth platforms that assist with prior authorizations is crucial to keeping costs manageable.
How this fits the bigger picture
The rise of Foundayo and the flattening demand for the oral Wegovy pill represent a critical inflection point in the broader GLP-1 market. This shift is occurring just as structural changes are making brand-name weight-loss drugs more accessible to seniors. On July 1, 2026, the federal government launched a landmark program designed to capped senior drug expenses, which we analyzed in our report on how Medicare launches a $50 copay cap for weight-loss GLP-1s. Under this Medicare Bridge program, eligible beneficiaries can access covered medications, including Foundayo, for a flat $50 monthly copayment.
However, as Eli Lilly USA President Ilya Yuffa noted, the company only began broad direct-to-consumer marketing after securing formulary access across three major pharmacy benefit managers (PBMs) in June 2026. This push is critical because commercial insurance coverage for weight loss is shrinking elsewhere. As we noted in our coverage of how employers cut GLP-1 coverage over soaring costs, an increasing number of private employers are dropping weight-loss benefits entirely.
This benefit contraction has forced many patients to bypass insurance and turn to online clinics. Clinical platforms like Found, which recently received high marks in industry evaluations for its insurance coordination and compound offerings—as outlined in our review of how U.S. News rates Found 4.6 stars—are becoming the primary access point for both oral brand names and compounded alternatives.
What happens next
The battle between Novo Nordisk and Eli Lilly over the oral market is only going to intensify. Eli Lilly is expected to ramp up its direct-to-consumer marketing campaigns for Foundayo throughout the second half of 2026, aiming to sustain its double-digit weekly script growth.
At the same time, telehealth platforms are expected to integrate Foundayo more deeply into their prescribing software, potentially offering it alongside compounded options to give cash-paying patients a broader spectrum of needle-free choices. Novo Nordisk will likely need to adjust its marketing or pricing strategies for the Wegovy pill to break through its current 33% franchise ceiling and prevent Lilly from dominating both the injectable and oral sectors of the U.S. obesity market.
Disclaimer: CompareRx does not provide medical advice. Always consult with a licensed healthcare provider to determine the best weight-loss treatment plan for your individual health needs.